Calculate the TIMI Risk Score for UA/NSTEMI by answering seven yes/no clinical questions. Enter patient details including age ≥ 65, CAD risk factors, known stenosis, ASA use, angina episodes, ST changes, and cardiac marker elevation — and get the TIMI score along with the corresponding 14-day risk percentage for death, MI, or urgent revascularization.
TIMI Score
--
14-Day Risk of Major Cardiac Event
--
Risk Category
--
The TIMI (Thrombolysis In Myocardial Infarction) Risk Score is a validated clinical tool that estimates the 14-day risk of major adverse cardiac events — including death, new or recurrent MI, or severe ischemia requiring urgent revascularization — in patients presenting with unstable angina or NSTEMI. It was developed by Antman et al. and published in JAMA in 2000.
The TIMI score is calculated by awarding 1 point for each of seven clinical criteria: age ≥ 65, three or more CAD risk factors, known coronary stenosis ≥ 50%, ST changes ≥ 0.5mm, two or more angina episodes in 24 hours, ASA use in the past 7 days, and a positive cardiac marker. Scores range from 0 to 7.
Higher scores indicate greater 14-day risk. A score of 0–1 carries about 5% risk, score 2 about 8%, score 3 about 13%, score 4 about 20%, score 5 about 26%, and scores 6–7 carry approximately 41% risk of death, recurrent MI, or urgent revascularization within 14 days.
The five recognized CAD risk factors in the TIMI score are: family history of coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, and being a current smoker. A patient must have three or more of these to score a point for this criterion.
No. There is a separate TIMI score designed specifically for STEMI (ST-segment Elevation Myocardial Infarction). The UA/NSTEMI version uses different criteria and predicts a different set of outcomes. Always use the appropriate score for the patient's presentation.
Scores of 5 to 7 are generally considered high risk, associated with a 26–41% probability of major cardiac events within 14 days. Scores of 3 to 4 represent intermediate risk (13–20%), and scores of 0 to 2 represent low risk (5–8%). Higher-risk patients typically benefit from early invasive strategies.
No. The TIMI score is a prognostic aid intended to support — not replace — clinical decision-making. It should be used alongside a full clinical assessment, physician evaluation, and institutional protocols. Individual patient circumstances may warrant different management regardless of the score.
Paradoxically, recent aspirin use is associated with higher risk in this population, likely because patients already taking aspirin who still develop ACS represent a sicker cohort with more advanced or refractory disease. It is a marker of pre-existing cardiovascular disease management rather than a causative factor.